Invention Grant
![Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide](/docs/US/2018-10-02/US10085993B2/abs.jpg.600x600.jpg)
- Patent Title: Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
-
Application No.: US15328661Application Date: 2015-07-22
-
Publication No.: US10085993B2Publication Date: 2018-10-02
- Inventor: Elisabete Goncalves , Christin Tauchmann , Shau-Fong Yen , Sudha Vippagunta , Zhixin Zong
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Jennifer C Chapman
- International Application: PCT/IB2015/055561 WO 20150722
- International Announcement: WO2016/012963 WO 20160128
- Main IPC: A61K31/53
- IPC: A61K31/53 ; A61K9/20
![Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide](/abs-image/US/2018/10/02/US10085993B2/abs.jpg.150x150.jpg)
Abstract:
The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
Public/Granted literature
Information query
